Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Free Cash Flow (2016 - 2025)

Apyx Medical (APYX) has disclosed Free Cash Flow for 15 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 11.85% year-over-year to -$2.8 million, compared with a TTM value of -$9.1 million through Dec 2025, up 51.44%, and an annual FY2025 reading of -$9.1 million, up 51.44% over the prior year.
  • Free Cash Flow was -$2.8 million for Q4 2025 at Apyx Medical, up from -$4.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $3.5 million in Q3 2023 and bottomed at -$6.4 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$3.3 million, with a median of -$3.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 3859.32% in 2022, then skyrocketed 163.48% in 2023.
  • Year by year, Free Cash Flow stood at -$118000.0 in 2021, then crashed by 3859.32% to -$4.7 million in 2022, then surged by 50.66% to -$2.3 million in 2023, then plummeted by 38.05% to -$3.2 million in 2024, then grew by 11.85% to -$2.8 million in 2025.
  • Business Quant data shows Free Cash Flow for APYX at -$2.8 million in Q4 2025, -$4.1 million in Q3 2025, and -$1.5 million in Q2 2025.